about
The impact of outpatient chemotherapy-related adverse events on the quality of life of breast cancer patientsThe Establishment of Indicators of Thrombocytopenia in Patients Receiving Lenalidomide Therapy.The impact of side effects from outpatient chemotherapy on presenteeism in breast cancer patients: a prospective analysis.Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin's lymphoma.Impact of levofloxacin dose adjustments by dispensing pharmacists on adverse reactions and costs in the treatment of elderly patients.Hyponatremia and hypokalemia as risk factors for falls.Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus.Medical and economic factors influencing generic drug use in the Japanese public health system: Influencing factors in different populations.Establishing an Indicator of Hypokalemia in Patients Receiving Anti-Epidermal Growth Factor Receptor Antibodies.The adoption of generic drugs by a hospital: effects on drug dispensation among community pharmacies.Impact of pharmacist counseling on reducing instances of adverse events that can affect the quality of life of chemotherapy outpatients with breast Cancer.[Predictors of Nivolumab-Induced Skin Reactions]Economic evaluation of adjustments of levofloxacin dosage by dispensing pharmacists for patients with renal dysfunctionFactors influencing the use of over-the-counter drugs and health foods/supplementsCost utility analysis of pharmacist counseling care for breast cancer chemotherapy outpatientsAnalysis of Adverse Reactions Caused by Potentially Inappropriate Prescriptions and Related Medical Costs That Are Avoidable Using the Beers Criteria: The Japanese Version and Guidelines for Medical Treatment and Its Safety in the Elderly 2015Relationship Between Initial Renal Function and the Inhibitory Effect of Dipeptidyl Peptidase-4 Inhibitor Treatment on Renal Function Decline[A female chronic myeloid leukemia patient who gave birth after stopping imatinib intentionally but who maintained a major molecular response with interferon][Analysis of factors influencing the occurrence of infusion reaction after initial treatment with rituximab]Risk factors contributing to urinary protein expression resulting from bevacizumab combination chemotherapy
P50
Q28546730-2FD04801-5A29-4364-A3F6-E3619485ED88Q33429494-527F24C8-8A93-405A-9EC8-F7B540471F09Q36686014-F91D870D-12EC-48F0-8BA1-69C2A980EA74Q40281244-0C75B415-514C-41C7-ABA7-410D7D8BDA0FQ43686712-6BC22D6B-3263-43DC-A30C-C1148A67C686Q44227609-160AF92A-F81F-4AA7-918F-4C881EBC8A3FQ46981976-90194BA4-0CB2-4DE9-9D67-ACB63905535EQ48281893-2A4AF8C7-E27E-432C-BDF0-E88755743AB8Q53124672-CB219A6D-EDBE-4748-98C4-EF18AA65EFD9Q53835939-A9E70036-4159-45C8-9415-16227F7C3846Q55027594-D5082F78-8935-424E-9802-58F0C8AA1BC6Q58124680-FD07B947-7CCE-46C3-9779-9DE19DCEF307Q86644139-32D02B3A-F589-4825-8083-AD07D5D71B7FQ91490366-3D78E2E0-73F8-48D9-B892-3935EE0720D8Q91751175-98B5F943-3002-4438-BDFE-4C604F4F75FCQ91804659-15D5A23E-4FBD-4FCA-A193-B9A370E9C117Q92353522-F846DDAD-E832-43E8-B945-EBC79E3B1B16Q95379011-95291CC9-BAE1-4B0E-9A4A-41F3A55595C0Q95487049-1171408D-F1C0-4380-81BD-170E07278082Q95526779-18BFB526-01C9-4B24-AEC7-CE2CD066088A
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
M Yasuda
@en
M Yasuda
@nl
type
label
M Yasuda
@en
M Yasuda
@nl
prefLabel
M Yasuda
@en
M Yasuda
@nl
P31
P496
0000-0003-4119-0149